Similar articles

• Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.

  Gierach GL, Curtis RE, Pfeiffer RM, Mullooly M, Ntowe EA, Hoover RN, Nyante SJ, Feigelson HS, Glass AG, Berrington de Gonzalez A. Gierach GL, et al. JAMA Oncol. 2017 Feb 9;3(2):186-193. doi: 10.1001/jamaoncol.2016.3340. Epub 2016 Oct 6. JAMA Oncol. 2017. PMID: 27711920 Free PMC article.
• [The effect of long-term tamoxifen therapy on the occurrence of contralateral primary breast cancer].

  Xing B, Huang X, Wang Y. Xing B, et al. Zhonghua Zhong Liu Za Zhi. 1996 Mar;18(2):143-5. Zhonghua Zhong Liu Za Zhi. 1996. PMID: 9206051 Clinical Trial. Chinese.
• Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group.

  Rutqvist LE, Mattsson A. Rutqvist LE, et al. J Natl Cancer Inst. 1993 Sep 1;85(17):1398-406. doi: 10.1093/jnci/85.17.1398. J Natl Cancer Inst. 1993. PMID: 8350363 Clinical Trial.
• Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.

  Jordan VC. Jordan VC. Breast Cancer Res Treat. 1995;36(3):267-85. doi: 10.1007/BF00713399. Breast Cancer Res Treat. 1995. PMID: 8573710 Review.
• Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.

  Gradishar WJ. Gradishar WJ. Oncology. 2005;69(1):1-9. doi: 10.1159/000087282. Epub 2005 Jul 28. Oncology. 2005. PMID: 16088229 Review.